Biblioteca Virtuale per la Salute – Piemonte – "Le biblioteche non si fanno…crescono" A. Birrell

Sfoglia per AUTORE
REDA G
Collezione AOU Novara

Items : 31

Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study. in Hematological oncology / Hematol Oncol. 2024 Jan;42(1):e3216. doi: 10.1002/hon.3216. Epub 2023 Sep 29.

2024
AO Cuneo
AOU Città della Salute di Torino
AOU Novara

Molica S; Iannella E; Malgieri S; Gozzetti A; Gualberti G; Caira M; Finsinger P; Reda G; Coscia M; Vallisa D; Pane F; Cuneo A; Albano F; Zamprogna G; Trentin L; Mauro FR; Albi E; Gaidano G; Laurenti L; Sportoletti P; Chiarenza A;

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS). in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2023 Oct 1;41(28):4486-4496. doi: 10.1200/JCO.22.02699. Epub 2023 Jun 9.

2023
ASL Biella
AOU Città della Salute di Torino
AOU Novara
AO Alessandria

Latagliata R; Zini G; Rizzo L; Bova I; D'Errigo MG; Cufari P; Arcadi MT; Delfino IM; Liberati AM; Candoni A; Rivellini F; Buccisano F; Stamatoullas-Bastard A; Ricco A; Palumbo GA; Impera S; Di Renzo N; Fenaux P; Germing U; Molteni A; Bocchia M; Beltrami G; Russo E; Castelli A; Fattizzo B; Guarini A; Tripepi G; Iannì G; Reda G; et alii...

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY. in EClinicalMedicine / EClinicalMedicine. 2023 Nov 15;65:102307. doi: 10.1016/j.eclinm.2023.102307. eCollection 2023 Nov.

2023
AOU Novara
AOU Città della Salute di Torino

Biderman B; Antic D; Angelopoulou M; Zuchnicka J; Yassin M; Yañez L; Yagci M; Xu Z; Wasik-Szczepanek E; Walewska R; Vukovic V; Vrachiolias G; von Tresckow J; Vitale C; Visentin A; Vassilakopoulos T; Tomic K; Tse E; Spacek M; Tadmor T; Abdelrahman Soliman DS; Smirnova S; Simkovic M; Shen Y; Schiwitza A; Schipani M; Daniel de Deus Santos M; Ruchlemer R; Rigolin GM; et alii...

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib. in Blood advances / Blood Adv. 2023 Jun 27;7(12):2794-2806. doi: 10.1182/bloodadvances.2022008821.

2023
AOU Città della Salute di Torino
AOU Novara

Scarfò L; Stamatopoulos K; Ranghetti P; Baliakas P; Cortese D; Österborg A; Walewska R; Pavlovsky C; Strugov V; Ysebaert L; Mulligan SP; Iyengar S; Coscia M; Frustaci AM; Jaksic O; Ringshausen I; Forconi F; Panayiotidis P; Marasca R; Tam CS; Stavroyianni N; Bödör C; Reda G; Trentin L; Bonello L; Gaidano G; Gandini F; Lyander A; Skaftason A; et alii...

Role of chemotherapy in the treatment of chronic lymphocytic leukemia in the era of targeted therapies in Italy. A Campus CLL network report. in Hematological oncology / Hematol Oncol. 2023 Feb;41(1):201-204. doi: 10.1002/hon.3047. Epub 2022 Aug 19.

2023
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU Novara

Marasca R; Foà R; Ballotta L; Moia R; Cuneo A; Chiurazzi F; Reda G; Gottardi D; Orsucci L; Maccaferri M; De Paoli L;

Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study. in American journal of hematology / Am J Hematol. 2023 Feb;98(2):E24-E27. doi: 10.1002/ajh.26779. Epub 2022 Nov 25.

2023
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara

Levi S; Trentin L; Foà R; Cuneo A; Herishanu Y; Gentile M; Perry C; Gattei V; Gaidano G; Rossi D; Neri A; Olivieri J; Bomben R; Zucchetto A; Visentin A; Loseto G; Pietrasanta D; Chiarenza A; Braester A; Murru R; Aviv A; Varettoni M; Coscia M; Tadmor T; Shvidel L; Sportoletti P; Laurenti L; Reda G; Ruchlemer R; et alii...

Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study. in Hematological oncology / Hematol Oncol. 2023 Dec;41(5):877-883. doi: 10.1002/hon.3199. Epub 2023 Jul 1.

2023
AO Cuneo
AOU Città della Salute di Torino
AOU Novara
AO Alessandria

Laurenti L; Cuneo A; Foà R; Trentin L; Coscia M; Rigolin GM; Gattei V; Mattiello V; Sportoletti P; Gentile M; Scortechini I; Moia R; Catania G; Loseto G; Chiurazzi F; Malerba L; De Paolis MR; Angeletti I; Ferrari A; Giordano A; Baratè C; Leone MMA; Quaresmini G; Farina L; Fresa A; Piciocchi A; Vitale C; Reda G; Visentin A; et alii...

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL. in American journal of hematology / Am J Hematol. 2023 Dec;98(12):1856-1868. doi: 10.1002/ajh.27093. Epub 2023 Sep 29.

2023
AOU Novara
AO Alessandria
AOU Città della Salute di Torino

Stamatopoulos K; Ghia P; Trentin L; Stavroyianni N; Vandenberghe E; Iyengar S; Coscia M; Rambaldi A; Montserrat E; Cuneo A; Vitale C; Segundo LYS; Pocali B; Yassin M; Wróbel T; Wasik-Szczepanek E; Van Der Spek E; van Gelder M; van Kampen R; Tonino SH; Te Raa D; Shrestha A; Saghumyan G; Mirás F; Reda G; Karlsson LK; Milosevic I; Del Poeta G; Gutwein O; et alii...

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.

2023
AO Alessandria
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
ASL Cuneo 1
AOU Novara

Cuneo A; Piciocchi A; Vignetti M; Fazi P; Foà R; Del Giudice I; De Propris MS; Nanni M; Molinari MC; Pietrasanta D; Mattiello V; Visentin A; Vitale C; Albano F; Neri A; De Novi LA; Tani M; Arcari A; Scarfò L; Giordano A; Gottardi D; Liberati AM; Galieni P; Patrizi VB; Deodato M; Musuraca G; Levato L; Marchetti M; Mannina D; et alii...

Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia. in Hematological oncology / Hematol Oncol. 2023 Aug;41(3):567-570. doi: 10.1002/hon.3080. Epub 2022 Oct 10.

2023
AOU Novara

Moia R; Dondolin R; De Propris MS; Talotta D; Mouhssine S; Perutelli F; Reda G; Mattiello V; Rigolin GM; Motta M; Olivieri J; Fanin R; Perbellini O; Ferrarini I; Mauro FR; Del Giudice I; Laurenti L; Tomasso A; Gentile M; Frustaci AM; Tedeschi A; Gozzetti A; Stelitano C; Visco C; Moreno C; Forconi F; Marasca R; Coscia M; Rossi D; et alii...

Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model. in American journal of hematology / Am J Hematol. 2022 May;97(5):E176-E180. doi: 10.1002/ajh.26502. Epub 2022 Feb 25.

2022
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AOU Novara

Mauro FR; Trentin L; Foa' R; Tedeschi A; Gaidano G; Cuneo A; Coscia M; Guarente V; Noto A; Ielo C; Deodato M; Del Poeta G; Stelitano C; Moia R; Giordano A; Levato L; Rigolin GM; Gentile M; Murru R; De Paoli L; Laurenti L; Vitale C; Ciolli S; Chiarenza A; Sportoletti P; Frustaci AM; Visentin A; Reda G; Giannarelli D; et alii...

Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study. in Haematologica / Haematologica. 2022 Jun 1;107(6):1470-1473. doi: 10.3324/haematol.2021.280325.

2022
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AOU Novara

Cuneo A; Laurenti L; Ghia P; Foà R; Trentin L; Pompili M; Tedeschi A; Mauro FR; Del Poeta G; Scarfò L; Autore F; Tomasso A; Di Sevo D; Arena V; Deodato M; Ielo C; Frustaci AM; Piciocchi A; Rughini A; Cassin R; Albano F; Quaglia FM; Pennese E; Moia R; Gentile M; Murru R; Motta M; Coscia M; Visentin A; et alii...

Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL. in Blood / Blood. 2022 Dec 1;140(22):2348-2357. doi: 10.1182/blood.2022016901.

2022
ASL Vercelli
AOU Città della Salute di Torino
AO Alessandria
AOU Novara

Ghia P; Colia M; Ranghetti P; Perotta E; Heltai S; Albi E; Scarano E; Schiattone L; Farina L; Moia R; Capasso A; Varettoni M; Laurenti L; Rivela P; Sancetta R; Coscia M; Motta M; Reda G; Ferrario A; Deodato M; Scarfò L;

Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. in Hematological oncology / Hematol Oncol. 2021 Oct;39(4):570-574. doi: 10.1002/hon.2899. Epub 2021 Jul 13.

2021
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
AO Alessandria
AOU Novara

Foà R; Orsucci L; Penna G; Chiarenza A; Gattei V; Gottardi D; Derenzini E; Levato L; Gozzetti A; Olivieri J; Murru R; Sanna A; Gentile M; Baratè C; Leone M; Stefoni V; Tisi MC; Malerba L; Ibatici A; Marasca R; Chiurazzi F; Varettoni M; Del Poeta G; Marchetti M; Farina L; Giordano A; Re F; De Paoli L; Foglietta M; et alii...

Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. in American journal of hematology / Am J Hematol. 2021 May 1;96(5):E168-E171. doi: 10.1002/ajh.26127. Epub 2021 Feb 24.